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Abstract
Introduction: McCune-Albright syndrome is a complex inborn disorder due to early embryonal postzygotic
somatic activating mutations in the GNAS1 gene. The phenotype is very heterogeneous and includes polyostotic
fibrous dysplasia, typically involving the facial skull, numerous café-au-lait spots and autonomous hyperfunctions of
several endocrine systems, leading to hyperthyroidism, hypercortisolism, precocious puberty and acromegaly.
Case presentation: Here, we describe a 12-year-old Caucasian girl with severe facial involvement of fibrous
dysplasia, along with massive acromegaly due to growth hormone excess and precocious puberty, with a
prolactinoma. Our patient was treated with a bisphosphonate and the prolactin antagonist, cabergoline, resulting
in the inhibition of fibrous dysplasia and involution of both the prolactinoma and growth hormone excess. During
a follow-up of more than two years, no severe side effects were noted.
Conclusion: Treatment with bisphosphonates in combination with cabergoline is a suitable option in patients with
McCune-Albright syndrome, especially in order to circumvent surgical interventions in patients suffering from
polyostotic fibrous dysplasia involving the skull base.
Introduction
McCune-Albright syndrome is a complex inborn disor-
der due to early embryonal postzygotic somatic activat-
ing mutations in the GNAS1 gene, which codes for a
number of different transcripts by alternative promoters
and alternative splicing. Among these, the Gs-alpha, the
XLAS, the NESP55 and the A/B transcripts are involved
in the regulation of bone metabolism and endocrine
functions [1-4].
The full phenotype of McCune-Albright syndrome
includes fibrous dysplasia, café-au-lait spots and autono-
mous hyperfunctions of several endocrine pathways
[2,5,6]. Bone disease may present as polyostotic or
monostotic fibrous dysplasia. Polyostotic involvement-
characterized by multiple separated foci of dysplasia-is
typically seen in the face but also in the extremities, or
both. Fibrous dysplasia of the extremities predisposes
for pathological fractures. Massive thickening of the
facial bones may lead to bizarre disfigurement with cos-
metic and psychosocial sequelae. Further, the encase-
ment of cranial nerves carries the risk of function loss,
like visual impairment; however, as recently shown by a
larger study, this is rare even in extended cases [7].
Sometimes the syndrome may lead to enhanced intra-
cranial pressure.
Autonomous hyperfunction in the endocrine glands
may typically manifest as precocious puberty or acrome-
galy, but also primary hyperthyroidism or hypercortiso-
lism. An excess of growth hormone and prolactin is, in
most cases, due to the diffuse hyperfunction of the ante-
rior pituitary lobe, but sometimes adenomas are found
[1]. A growth hormone excess and lesions of fibrous
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dysplasia have mutual effects on phosphate levels, as
growth hormone-mediated phosphate reabsorption is
counteracted by phosphaturic substances secreted from
fibrous dysplastic lesions. Thus, acromegaly in McCune-
Albright syndrome has several features that are specific
to this disease [1]. In rare cases, hepatobiliary disorders,
cardiomyopathy, proximal tubulopathies, nephrocalcino-
sis and hypophosphatemic rickets are observed in
McCune-Albright syndrome [1-4].
The syndrome is very polymorphic and the degree of
skeletal or endocrine abnormality is heterogeneous.
Thus it should be considered in all cases of fibrous dys-
plasia or in pituitary hyperfunctions [1,6].
Here, we describe a case of McCune-Albright syn-
drome with severe facial disfigurement due to fibrous
dysplasia, acromegaly, precocious puberty and a pituitary
adenoma. The girl was successfully treated over years
with pamidronic acid to inhibit progressive fibrosis and
cabergoline as a prolactin antagonist effective against
the adenoma.
Case presentation
Our patient was the third child of non-consanguineous
Caucasian parents; her father died from cystic kidney
disease when she was three years old. Her birth and
neonatal development were uneventful.
At the age of three years, skull asymmetry became
visible, which was more and more pronounced in the
following years. Fibrous dysplasia was identified by
computed tomography, involving in particular the left
skull base with the optic canal. Café-au-lait spots were
not visible. Beginning at the age of five, the girl under-
went five subsequent surgical interventions for plastic
reconstruction of her face. However, after each sur-
gery, the girl experienced a marked regrowth of the
dysplasia leading to massive facial disfigurement (Fig-
ure 1).
Finally, at the age of eleven years, our patient pre-
sented with gigantism, leading to endocrinological
examinations. Her pubertal development now showed
Tanner stage PH2-3, B2-3; her body weight was 80.8 kg
and length 175.2 cm (both above than the 97th percen-
tile). Besides the asymmetrical skull dysplasia, the girl
also presented with an acromegalic appearance. Labora-
tory evaluations revealed a massive hyperprolactinemia
of 5475 mU/L (normal range < 500 mU/L), high growth
hormone levels (that is, 43.2 mU/mL at 8 a.m.), and an
elevated insulin-like growth factor 1 (IGF-1) of 892 ng/
mL (age-related normal range, 111 ng/mL to 693 ng/
mL). Her alkaline phosphatase was 690 U/L (normal
range, 51 U/L to 332 U/L). A pituitary adenoma was
seen on magnetic resonance imaging, located within the
massively expanded dysplastic skull base (Figure 2). An
ophthalmological examination revealed neither diplopia
Figure 1 Three-dimensional reconstruction with volume
rendering from a computed tomography scan of her skull.
Shows facial disfigurement due to extended bone distensions with
mixed radiolucent and sclerotic focal lesions.
Figure 2 T2-weighed sagittal magnetic resonance image. Shows
massive thickening of her skull base due to fibrous dysplasia and a
pituitary adenoma.
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nor any other subjective impairment of her vision. There
was a mild paleness of her optic nerve papilla and mild
left-sided hemianopia.
The case was discussed in a multidisciplinary confer-
ence for the four problems, that is, her facial disfigure-
ment, possible danger to her left visual nerve and the
pituitary tumor leading to local pressure and acrome-
galy. Besides the futility and probable enormous diffi-
culty of cosmetic surgery, our patient and her mother
refused any further surgical interventions for this pur-
pose. A surgical intervention at her pituitary gland
appeared difficult due to its complete impaction within
the dysmorphic, fibrous bone of her skull base. There-
fore, we did not obtain a histopathology specimen, and
so it was not possible to tell whether the pituitary
tumor was a lesion of acidophils, prolactin cells or both.
Radiotherapy of her pituitary gland by conventional or
gamma-knife irradiation was considered as too toxic,
especially since malignant transformation is a well-
known possible late effect, particularly in fibrous dyspla-
sia tissues [8].
Thus, based on published experiences in McCune-
Albright syndrome [1,2,9,10], at the age of twelve years,
our patient started pharmacological treatment. First, to
treat the fibrous dysplasia, we initiated parenteral
bisphosphonate therapy with pamidronic acid (Aredia),
given every four weeks with a dosage of 30 mg, which
equals about 0.4 mg per kilogram body weight. This was
done by continuous infusion over four hours with cardi-
orespiratory monitoring and included regular examina-
tion of her kidney and liver function parameters.
In parallel, cabergoline, as the current standard ther-
apy of prolactinomas, was given with a stepwise escala-
tion of the dosage to reach a level of 2 mg twice weekly,
which was tolerated well. Regular controls of blood
pressure and cardiac function were included.
The clinical course was monitored regularly in
monthly to three monthly intervals. The therapy was
tolerated well. No acute side effects, such as rash, nau-
sea, electrolyte disturbances, cardiovascular, pulmonary
or renal impairment, occurred. Further, the continuous
treatment, which has been extended without change for
two and a half years, was not associated with osseous
necrosis of the jaw or elsewhere, nephrocalcinosis or
cardiac valve fibrosis.
Magnetic resonance imaging showed no further pro-
gression of the fibrous dysplasia; her osseous status has
remained unchanged for two and a half years. Her alka-
line phosphatase, initially elevated up to 690 U/L,
declined to 587 U/L after one year, and 417 U/L after
two years of therapy.
Her visually evoked potentials showed a mild prolon-
gation after the first six months of therapy, which did
not go along with any subjective symptoms.
Endocrinological tests showed an immediate and rapid
response of prolactin, which fell to the normal range
within two months of therapy and have remained com-
pletely suppressed since. In parallel, we observed a nor-
malization of her growth hormone levels, and her IGF-1
level fell to normal levels after four months. The growth
of our patient slowed down, her final length of 180 cm
was, however, much higher than her mid parental
expectation. Our patient achieved menarche about one
year after the initiation of treatment, that is, several
months after normalization of her prolactin levels. Mag-
netic resonance imaging of her skull base showed a
marked shrinkage of the hypophyseal tumor.
In summary, we observed stabilization both of the oss-
eous and the endocrinological symptoms of the disease
in our patient, allowing a significant improvement in the
quality of life of our patient without further surgical
interventions.
Discussion
The clinical symptoms of McCune-Albright syndrome
in our patient were related to both bone and endocrine
involvement, that is, facial disfigurement caused by
excessive bone growth and acromegaly with visual
nerve encasement, and the growth of a pituitary
tumor. For both problems, surgical treatment was not
applicable.
It has recently been described that treatment with
bisphosphonates may be an effective measure in fibrous
dysplasia [1,5,6,10], although randomized trials are lack-
ing. Chemically, bisphosphonates, among which pami-
dronic acid is commonly used, are simple
pyrophosphate derivatives interfering with phosphate
metabolism in osteoclasts. This leads to inhibition or,
ultimately, apoptosis of these cells [10]. Typically,
bisphosphonates are used in the treatment of osteolytic
metastases of adult carcinomas, both in order to reduce
pain and to slow tumor growth or progression [11].
In children and adolescents, bisphosphonate therapy
appears to be well tolerated in general, even in long-
term treatment [10,12]. In these cases, they are applied
in rare disorders of calcification, like osteogenesis
imperfecta, congenital or malignoma-induced hypercal-
cemia, osteoporosis, or, as in our case, fibrous dysplasia.
Side effects of bisphosphonates include acute phase
reactions, dyspepsia, esophagitis, iritis or osteonecrosis,
especially in the jaw. However, in general, the treatment
is well tolerated in children and adolescents; particularly,
osteonecrosis is practically absent [5,10]. Several authors
have already described a partial or complete arrest of
fibrous dysplasia on bisphosphonate treatment in chil-
dren and adolescents [2], with good tolerance even
upon long-term treatment. Chan and Zacharin observed
a progress of fibrous dysplastic lesions in spite of
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pamidronic acid treatment in long bones, but an arrest
of fibrous dysplasia in facial bones [13].
Cabergoline is a synthetic ergot alkaloid which per-
forms as a long acting D2-selective dopamine agonist,
inhibiting D2 receptor-mediated prolactin secretion in
the anterior lobe of the pituitary gland [14]. Pharma-
cological treatment of pituitary adenomas by cabergo-
line primarily aims at inhibition of prolactin
stimulation, leading to the involution of prolactino-
mas. In recent years, it been shown that cabergoline is
more effective than the previous standard, bromocrip-
tine. However, some efficacy has also been described
in growth hormone inhibition and inhibition of other
anterior pituitary hormones, such as adrenocorticotro-
pic hormone [1]. In a larger cohort, Akintoye et al.
observed normalization of IGF-1 in most patients trea-
ted with cabergoline, long-acting octreotide, or both
[1].
Side effects of cabergoline include arterial hypotonia,
fatigue, depression, dyspepsia, nausea and vomiting,
cramps and erythema; an effect of particular concern is
cardiac valve pathology, especially valve thickening [14].
The relevance of this has recently been questioned [15].
In our patient, we observed no relevant side effects; in
particular, we saw no cardiac abnormalities after more
than two years of continuous treatment.
The combination of prolactinoma with growth hor-
mone excess is typical in McCune-Albright syndrome,
leading to an early manifestation acromegaly that may
enhance the asymmetric facial disfigurement [5,14]. In
cases in which cabergoline alone is not sufficient to stop
growth hormone excess, the somatostatin analogue
octreotide or the growth hormone receptor antagonist
pegvisomant may be additionally beneficial for the treat-
ment of acromegaly [3,11]. In our patient, this appeared
not to be necessary, since her IGF-1 levels went down
to normal and the development of acromegaly was
arrested.
Conclusion
Thus, treatment with bisphosphonates in combination
with cabergoline successfully arrested both her dysplas-
tic bone growth and endocrine malfunction, without
severe side effects. We believe that this approach is a
suitable option in patients with McCune-Albright syn-
drome, especially in order to circumvent surgical inter-
ventions that might be of particular risk in patients
suffering from polyostotic fibrous dysplasia involving the
skull base.
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